

.....
Report of the
WHO Informal Consultation
on the use of Praziquantel
during Pregnancy/Lactation
and Albendazole/Mebendazole
in Children under 24 months

.....

Geneva

8-9 April 2002



World Health Organization
Strategy Development and Monitoring
for Parasitic Diseases and Vector Control (PVC)
Prevention, Control and Eradication (CPE)
Communicable Diseases (CDS)
<http://www.who.int/ctd>

**REPORT OF THE WHO INFORMAL CONSULTATION ON THE USE
OF PRAZIQUANTEL DURING PREGNANCY/LACTATION
AND ALBENDAZOLE/MEBENDAZOLE
IN CHILDREN UNDER 24 MONTHS**

GENEVA
8-9 April 2002



World Health Organization
Strategy Development and Monitoring for Parasitic Diseases and Vector Control
(PVC)

Control, Prevention and Eradication (CPE)
Programme on Communicable Diseases (CDS)
<http://www.who.int/health-topics/>

This Consultation and the production of this report
was made possible thanks to the financial support of the:
Direction de la Coopération multilatérale, Direction générale de la Coopération,
Government of Belgium

© World Health Organization 2003

All rights reserved.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.

TABLE OF CONTENTS**Page No.**

List of participants	5
1. Purpose of the consultation.....	9
2. Public health significance of schistosomiasis in pregnant and lactating women	10
3. Public health significance of soil-transmitted helminthiasis in children under 24 months	11
4. Pathophysiological aspects	
4.1 Schistosomiasis during pregnancy and lactation.....	12
4.2 Soil-transmitted helminthiasis during early childhood (0-24 months).....	13
5. Praziquantel (PZQ)	
5.1 Mode of action.....	14
5.2 Pharmacokinetics.....	14
5.3 Toxicity	15
5.4 Notified inadvertent use and recorded adverse effects.....	16
6. Albendazole (ALB)	
6.1 Mode of action	16
6.2 Pharmacokinetics	16
6.3 Toxicity	17
6.4 Notified inadvertent use and recorded adverse effects.....	18
7. Mebendazole (MBD)	
7.1 Mode of action	21
7.2 Pharmacokinetics	21
7.3 Toxicity	21
7.4 Notified inadvertent use and recorded adverse effects	22

8. Conclusions concerning the use of praziquantel (PQZ) for the treatment of schistosomiasis during pregnancy and lactation	23
9. Conclusions concerning the use of albendazole (ALB) and mebendazole (MBD) in the treatment of soil-transmitted helminthiasis in children under 24 months	24
10. Drug interactions	25
11. Benefits of schistosomiasis treatment for the health of pregnant and lactating women and for birth outcome	26
12. Benefits of soil-transmitted helminthiasis treatment for the health of children under 24 months.....	27
13. Risk analysis of using praziquantel to treat pregnant and lactating women for schistosomiasis	28
14. Risk analysis of using albendazole or mebendazole to treat children under 24 months for soil-transmitted helminthiasis	29
15. Use of levamisole (LEV) and pyrantel (PYR) in children under 24 months for the treatment of soil-transmitted helminthiasis	30
16. Drug procurement, quality assurance and monitoring	30
17. Issues requiring further attention.....	31
18. Recommendations	32
References	35
Glossary of key terms and abbreviations used in the report	40
Appendix I Review papers	44
Appendix II Extracts from WHO Model Formulary 2002	45

List of participants

Dr M. Albonico, Fondazione Ivo de Carneri, via. IV Marzo 14,
10122 Turin, Italy
email address: albonico@tin.it

Professor S. Awasthi, Department of Paediatrics and Institute of
Clinical Epidemiology, Upgraded KG Medical College, CSM Medical
University, Lucknow (UP) 226003, India
email address: sawasthi@sancharnet.in

Professor R. Barakat, High Institute of Public Health, 165 El Hoerrya
Street, Alexandria, Egypt
email address: Barakat@dataxprs.com.eg

Dr L. Brabin, Women's Health, Academic Unit of Obstetrics,
Gynaecology & Reproductive Health Care, Whitworth Park,
Manchester M130JH, UK
email address: loretta.brabin@man.ac.uk

Professor D.W.T. Crompton, Institute of Biomedical & Life Sciences,
University of Glasgow, Graham Kerr Building, Glasgow G128QQ,
Scotland
(Rapporteur)
email address: dwtc@tyndrum.demon.co.uk

Professor A. Dayan, 21 Heathgate, London NW11 7AP, UK
email address: a.dayan@toxic.u-net.com

Professor P. Folb, Department of Pharmacology, Medical School,
University of Cape Town, K45 Old Main Building, Observatory,
7925 Cape Town, South Africa
email address: pfolb@uctgsh1.uct.ac.za

Professor P. Hagan, University of Glasgow, Institute of Biomedical &
Life Sciences, Division of Infection and Immunity, Joseph Black
Building, Glasgow G128QQ, UK
email address: P.Hagan@bio.gla.ac.uk

Dr G. Helling-Giese, Tropenmedizinische Ambulanz,
Universitätsklinikum Düsseldorf, Moorensrt. 5 Düsseldorf, D40225,
Germany
email address: g.helling-giese@freenet.de

Dr C. Holland, Department of Zoology, Trinity College, Dublin 2,
Ireland
(*Rapporteur*)
email address: cholland@mail.tcd.ie

Dr C. King, Division of Geographic Medicine, W137 Case Western
Reserve University, Cleveland, Ohio 44106-4983, USA
email address: chk@po.cwru.edu

Dr G. R. Olds, The Linda and John Mellowes Professor and
Chairman, Medical College of Wisconsin, Department of Medicine,
9200 W. Wisconsin, Avenue, FECOB 4100, Milwaukee,
Wisconsin 53226, USA
email address: grolds@mcw.edu

Dr N. de Silva, Department of Parasitology, Faculty of Medicine,
University of Kelaniya, P.O. Box 6, Talagolla Road, Ragama,
Sri Lanka
(*Chairperson*)
email address: nrdes@sltnet.lk

Dr R. Stoltzfus, Johns Hopkins University, Division of Human
Nutrition, Department of International Health, School of Hygiene and
Public Health, 615, North Wolfe Street, 21205-2179 - Baltimore, USA
email address: rstoltzf@jhsph.edu

Dr S. Sulaiman, Director, TMRI, P.O. Box 1304, 1111 Khartoum,
Sudan
email address: tropmed@sudanmail.net

Dr H. Torlesse, Hellen Keller International, P.O Box 6066, Gulshan,
Dhaka 1212, Bangladesh
email address: htorlesse@hkidhaka.org, htorlesse@hotmail.com

Dr Sen-Hai Yu, Institute of Parasitic Diseases, Chinese Center for
Disease, Control and Prevention, 207, Rui Jin Er Road, Shanghai,
200025, China
email address: yusenhai@yahoo.com

WHO Secretariat:

Dr S. Aboubaker, Child and Adolescent Health and Development,
Family and Community Health - email: aboubakers@who.int

Dr L. Chitsulo, Research Capability Strengthening, WHO Special
Programme for Research and Training in Tropical Diseases
email: chitsulol@who.int

Dr M. Couper, Quality Assurance and Safety: Medicines, Department
of Essential Drugs and Medicines Policy - email: couperm@who.int

Dr D. Engels, Strategy Development and Monitoring for Parasitic
Diseases and Vector Control, Communicable Disease Control,
Prevention and Eradication - email: engelsd@who.int

Dr R. Kabra, Making Pregnancy Safer, Family and Community Health
email: kabrar@who.int

Dr J. Lazdins-Helds, Product Research and Development, WHO
Special Programme for Research and Training in Tropical Diseases
email: lazdinsj@who.int

Dr A. Montresor, Strategy Development and Monitoring for Parasitic
Diseases and Vector Control, Communicable Disease Control,
Prevention and Eradication - email: montresora@who.int

Dr L. Muhe, Child and Adolescent Health and Development, Family
and Community Health - email: muhel@who.int

预览已结束，完整报告链接和

<https://www.yunbaogao.cn/report/index/report>